Data-Driven Science and Leadership

In this episode, Dominic Schumacher explains how Tubulus is redefining antibody drug conjugates (ADCs) with a proprietary phosphonamidate chemistry. By anchoring the chemotherapeutic payload to a phosphorus‑based linker, the company prevents premature release, dramatically widening the therapeutic window and allowing the drug to strike tumors while sparing healthy cells. This chemistry addresses a long‑standing challenge in ADC development and positions Tubulus’s platform as a next‑generation solution for solid‑tumor indications such as ovarian and lung cancer.

Schumacher also highlights the strategic value of deep partnerships with industry giants Bristol Myers Squibb and Gilead. These collaborations are built on mutual trust, enabling rapid data sharing and joint problem‑solving that accelerates clinical progress. Internally, he stresses a culture rooted in data‑driven decision‑making and transparent communication, where listening to team motivations and maintaining personal connections across global sites keep the organization aligned. This leadership approach balances scientific rigor with the human elements essential for scaling a biotech startup.

Looking ahead, Schumacher predicts ADCs will become standard across earlier treatment lines, expanding beyond niche indications to become a backbone of cancer therapy. The broader therapeutic windows achieved through phosphorus chemistry could support multiple dosing levels and improve patient quality of life. For founders, he advises focusing on rational, data‑backed narratives when fundraising, cultivating anchor investors, and staying adaptable when strategic pivots arise—such as shifting from liquid to solid tumor targets. The episode underscores that scientific innovation, trustworthy partnerships, and disciplined leadership together drive sustainable growth in biotech.